OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”). Each subscription right now entitles holders to purchase one unit (th ...

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3, 2026. The su ...

Core Viewpoint - AIM ImmunoTech Inc. is advancing its Phase 2 clinical study of Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, with promising early results and a commitment to ongoing updates [1][2][4]. Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial with 18 subjects enrolled, focusing on patients with stable disease post-FOLFIRINOX [2]. - The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center, with interim progress reports planned for mid-year and year-end [2]. - The lead investigator reported continued promising results in Progression-Free Survival and Overall Survival from Phase 1, supporting the ongoing Phase 2 study [2]. Group 2: Safety and Quality of Life - There has been no significant toxicity reported, indicating a favorable safety profile for Ampligen in a post-chemotherapy setting [3]. - Subjects receiving Ampligen have consistently reported a "high quality of life" during treatment [3]. Group 3: Future Milestones - Key milestones include completing subject enrollment by July 2026, full dosing by August 2026, and evaluating primary and secondary endpoints by December 2026 and June 2027, respectively [5]. - The primary endpoint is the Clinical Benefit Rate at 6 months, while secondary endpoints include Progression-Free Survival, Overall Survival, and immunogenic efficacy [5]. Group 4: Corporate Strategy - AIM emphasizes the potential for Ampligen's approval in pancreatic cancer, viewing this research as a significant opportunity for stockholders [4]. - The company aims to advance Ampligen towards Phase 3 clinical trials, which are often associated with substantial financial opportunities in the biotech sector [4].

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Focus**: Development of Ampligen for the treatment of pancreatic cancer, a significant unmet medical need [1][3] Core Points and Arguments Strategic Focus on Pancreatic Cancer - AIM ImmunoTech has refined its development focus to prioritize pancreatic cancer due to its high lethality and lack of effective therapies [8][15] - The company believes Ampligen can alter the immunosuppressive status of tumors, leading to therapeutic effects in solid tumors, particularly pancreatic cancer [8][9] Market Need and Opportunity - Pancreatic cancer results in over 100,000 deaths annually in the U.S. and EU, with more than 450,000 deaths worldwide [11][13] - The company sees a moral obligation to address this unmet medical need, as current therapies are inadequate [9][15] - Ampligen has shown potential to extend overall survival beyond historical controls, with a median extension of over 8 months [39][84] Clinical Development and Data - The company has treated approximately 75 subjects in its phase II trials, demonstrating a strong safety profile and positive efficacy data [18][19][39] - Ampligen is positioned as both a monotherapy and a combination therapy, enhancing the effectiveness of checkpoint inhibitors [32][34] Business Model and Regulatory Strategy - AIM ImmunoTech aims to develop Ampligen to a stage suitable for acquisition by a larger pharmaceutical company [16][17] - The company has received orphan drug designations from the U.S. and EU, providing market exclusivity for an extended period post-approval [16][67] - The business model is supported by a strong intellectual property portfolio and positive clinical results [62][68] Future Plans and Milestones - The company is planning to transition from phase II to phase III trials, with a focus on designing a robust trial protocol [19][46] - AIM ImmunoTech anticipates announcing specific milestones related to the completion of phase II and the design of phase III trials [54][76] Additional Important Content - The company has collaborated with major pharmaceutical companies and research institutes, enhancing its credibility and resource access [25][24] - Ampligen's mechanism of action involves restoring the immune system, which is often compromised in cancer patients, thus improving their quality of life [28][30] - The company emphasizes the importance of designing trials that ensure success and drug approval, leveraging data from previous studies to inform current strategies [40][45] Conclusion - AIM ImmunoTech is strategically positioned to address a critical need in pancreatic cancer treatment with its lead product, Ampligen. The company is focused on advancing its clinical trials and securing partnerships to enhance its market presence and therapeutic impact [88][90]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - TG-17, Inc. (OBAI) has increased by 123% to $6.98 [3] - Polaryx Therapeutics, Inc. (PLYX) is up 78% at $4.29 [3] - ZIM Integrated Shipping Services Ltd. (ZIM) has risen by 34% to $29.97 [3] - Masimo Corporation (MASI) is up 33% at $173.80 [3] - Ocular Therapeutix, Inc. (OCUL) has increased by 26% to $11.21 [3] - Empery Digital Inc. (EMPD) is up 15% at $4.34 [3] - Digital Brands Group, Inc. (DBGI) has risen by 12% to $5.40 [3] - Kennedy-Wilson Holdings, Inc. (KW) is up 9% at $10.82 [3] - urban-gro, Inc. (UGRO) has increased by 8% to $3.89 [3] - Neo-Concept International Group Holdings Limited (NCI) is up 6% at $2.55 [3] Premarket Losers - JIADE Limited (JDZG) has decreased by 48% to $1.98 [4] - AIM ImmunoTech Inc. (AIM) is down 19% at $1.01 [4] - Founder Group Limited (FGL) has fallen by 16% to $15.10 [4] - Mega Fortune Company Limited (MGRT) is down 12% at $6.53 [4] - Moolec Science SA (MLEC) has decreased by 9% to $7.80 [4] - Creative Global Technology Holdings Limited (CGTL) is down 8% at $2.68 [4] - Danaher Corporation (DHR) has fallen by 7% to $196.00 [4] - Westwood Holdings Group, Inc. (WHG) is down 7% at $16.37 [4] - Psyence Biomedical Ltd. (PBM) has decreased by 6% to $2.90 [4] - Healthcare Triangle, Inc. (HCTI) is down 5% at $8.10 [4]

Core Viewpoint - Falcon Oil & Gas Ltd. is set to cancel its admission to trading on AIM following a transaction with Tamboran Resources Corporation, which involves the issuance of shares and a cash payment to Falcon shareholders [2][3]. Transaction Details - The transaction includes Tamboran issuing 6,537,503 shares of its common stock to Falcon and a cash payment of $23,663,080 [3]. - Falcon shareholders, excluding dissenting shareholders or those subject to sanctions, will receive shares of Tamboran in exchange for their Falcon common shares [3]. Conditions for Completion - The completion of the transaction is contingent upon several approvals, including: - Approval from Falcon shareholders at a meeting scheduled for March 11, 2026 [4]. - Approval of the stock issuance by Tamboran stockholders [4]. - Approval of the plan of arrangement by the Supreme Court of British Columbia [4]. - No material adverse changes affecting either Falcon or Tamboran [4]. Timeline for AIM Cancellation - Falcon is required to provide at least 20 business days notice for the AIM Cancellation [5]. - If all conditions are met, the transaction is expected to close around March 16, 2026, with trading of Falcon's common shares on AIM suspended on March 17, 2026, and the cancellation effective on March 18, 2026 [5].

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen®, aimed at treating late-stage pancreatic cancer, with an expected gross proceeds of $12 million if fully subscribed [2][5]. Group 1: Rights Offering Details - The rights offering allows holders of the company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [3][4]. - Each unit consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock, with the preferred stock convertible into 833 shares of common stock at a conversion price of $1.20 per share [4]. - The subscription rights are non-transferable and must be exercised by 5:00 p.m. Eastern Time on February 27, 2026, unless extended by the company [6]. Group 2: Financial Implications - If the rights offering is fully subscribed, the company anticipates receiving aggregate gross proceeds of $12 million [5]. - Holders who fully exercise their basic subscription rights will have the opportunity to subscribe for additional units that remain unsubscribed due to unexercised basic subscription rights [5]. Group 3: Company Background - AIM ImmunoTech Inc. is focused on the research and development of Ampligen® (rintatolimod), which is a highly selective TLR3 agonist immuno-modulator showing promise in treating late-stage pancreatic cancer [12].

Core Viewpoint - AIM ImmunoTech is set to present its lead program, Ampligen, for the treatment of pancreatic cancer during a virtual investor event on February 19, 2026, highlighting its clinical and regulatory strategy [1][2]. Group 1: Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing Ampligen (rintatolimod) for late-stage pancreatic cancer, addressing a significant global health issue [4]. - Ampligen is characterized as a dsRNA and highly selective TLR3 agonist immuno-modulator, demonstrating broad-spectrum activity in clinical trials [4]. Group 2: Event Details - Thomas K. Equels, the CEO of AIM, will participate in a Virtual Investor Closing Bell Event on February 19, 2026, at 4:00 PM ET [1]. - The event will emphasize the ongoing DURIPANC clinical trial, which involves a collaboration with AstraZeneca, combining Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi (durvalumab), for treating metastatic pancreatic cancer [2]. - A live video webcast of the presentation will be available on the company's website, with a replay accessible for 90 days after the event [3].

AIM ImmunoTech Conference Summary Company Overview - AIM ImmunoTech is a late-stage immunopharma company focused on the drug Ampligen (rintatolimod), which has shown efficacy and safety in various solid tumors, particularly in oncology since its repurposing from chronic fatigue syndrome in 2016-2017 [1][2] Core Points and Arguments - **Pancreatic Cancer Focus**: The company is prioritizing the approval of Ampligen for pancreatic cancer, having initiated a program in 2017 with a Dutch government-approved early access program for late-stage patients [2][4] - **Clinical Trials**: Currently conducting a Phase I-II trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) at Erasmus Medical Center, with approximately 75 subjects treated so far [2][6] - **Mechanism of Action**: Ampligen is described as converting "cold tumors" into "hot tumors" by altering the tumor microenvironment, specifically the ratio of suppressor T cells to killer T cells [3][4] - **Safety Profile**: The drug has a well-established safety profile with over 100,000 IV doses administered, and approvals for various administration methods [4][5] - **Market Opportunity**: The company sees a significant opportunity in the pancreatic cancer market, supported by patent and orphan drug designations that provide market exclusivity [5][6] Key Data and Results - **Survival Benefits**: In the early access program, the median overall survival for 57 subjects was 19.7 months, compared to 12.5 months for the standard of care, resulting in an 8.6-month survival benefit [8][17] - **Quality of Life**: Patients reported significant improvements in quality of life, which is crucial given the poor quality of life associated with late-stage pancreatic cancer [8][19] - **Immunological Markers**: Specific biomarkers, such as the neutrophil-lymphocyte ratio and CA19-9 levels, have been identified as predictive of Ampligen's response and overall survival [9][10] Future Milestones - **DURIPANC Program**: The program aims to treat 25 subjects, with 18 currently in treatment. The last subject is expected to be treated by the end of the year, which will be a significant milestone [20][21] - **Phase III Trial Planning**: The company is already planning for a Phase III trial, with the goal of demonstrating continued positive impacts on survival and quality of life [21][22] Additional Important Information - **Patent Protection**: A recent U.S. patent covering Ampligen in combination with PD-L1 for various cancers is valid until 2039, enhancing the company's market position [5][6] - **Orphan Drug Designation**: This designation provides up to 10 years of market protection in the EU, commencing upon drug approval, which is critical for the company's strategy [6][7] This summary encapsulates the key points from the AIM ImmunoTech conference, highlighting the company's focus on pancreatic cancer, the efficacy and safety of Ampligen, and the strategic planning for future clinical trials and market opportunities.

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][10] Rights Offering Details - The rights offering allows holders of the Company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [2][4] - Each subscription right entitles the holder to purchase one unit, which consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock [3] - The preferred stock is convertible into 833 shares of common stock at a conversion price of $1.20 per share, and each warrant is exercisable for one share of common stock at the same exercise price [3] Financial Projections - If fully subscribed, the rights offering is expected to generate gross proceeds of $12 million [4] - Holders who fully exercise their basic subscription rights can subscribe for additional units that remain unsubscribed [4] Subscription Period - The subscription period commenced on February 11, 2026, and will end on February 27, 2026, unless extended by the Company [5] - Subscription rights are non-transferable and must be exercised during the subscription period [5] Management and Regulatory Information - Maxim Group LLC has been engaged as the dealer-manager for the rights offering [6] - The offering is made pursuant to a registration statement declared effective by the SEC on February 10, 2026 [7]